EpicGenetics Announces Important Reminders for Fibromyalgia Clinical Trial Eligibility
LOS ANGELES--(BUSINESS WIRE)--Oct 2, 2018--Last month, EpicGenetics announced that the U.S. Food and Drug Administration (FDA) has approved the Massachusetts General Hospital for a human clinical trial of BCG (an inexpensive generic vaccine used globally to prevent tuberculosis) to treat and reverse the biology of fibromyalgia. Now, in response to an outpouring of related interest from patients with suspected fibromyalgia, EpicGenetics has issued reminders for those wanting to volunteer for this first-ever direct fibromyalgia treatment trial.
EpicGenetics, Inc. developed and offers an approved and confirmatory fibromyalgia diagnostic medical blood test that identifies the immune system biomarkers of this disease, the FM/a® Test. The first and most important thing to know is that those who want to volunteer for the upcoming clinical trial must have been medically diagnosed and confirmed as having fibromyalgia.
Second, and particularly relevant with the flu season here, is that most vaccinations, including the flu shot, may temporarily interfere with the FM/a® Test. Patients must wait 90 days after any vaccination to undergo the FM/a® Test. It is important that patients schedule their FM/a® Test before getting vaccinated.
“It’s so important to raise awareness of the clinical treatment trial within the fibromyalgia community,” said Bruce Gillis, M.D., CEO of EpicGenetics. “We want to ensure that anyone wishing to volunteer for this treatment trial is aware of the impact flu shot vaccinations may have on eligibility. We therefore want them to undergo their FM/a® test as soon as possible and still have their flu shot soon, too.”
Dr. Gillis has been an advocate for fibromyalgia patients since he and his research team at the University of Illinois, College of Medicine at Chicago discovered unique immune system, cellular and protein abnormalities which are associated with the disease of fibromyalgia six years ago. To find out more information about the FM/a Test visit https://fmtest.com/.
EpicGenetics, Inc. is a privately held biomedical company based in Los Angeles, California, that developed and manufactures the FM/a ® Test. EpicGenetics is dedicated to improving the diagnosis and treatment of fibromyalgia by offering the first conclusive diagnostic test for fibromyalgia, and by investing in and developing further comprehensive clinical studies at leading medical research centers. More information is available at www.FMTest.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181002005291/en/
CONTACT: EpicGenetics, Inc.
(310) 824-9000 (office)
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS HOSPITALS PHARMACEUTICAL RESEARCH FDA SCIENCE GENERAL HEALTH
SOURCE: EpicGenetics, Inc.
Copyright Business Wire 2018.
PUB: 10/02/2018 09:00 AM/DISC: 10/02/2018 09:01 AM